AU2022402322A1 - Treatment - Google Patents

Treatment Download PDF

Info

Publication number
AU2022402322A1
AU2022402322A1 AU2022402322A AU2022402322A AU2022402322A1 AU 2022402322 A1 AU2022402322 A1 AU 2022402322A1 AU 2022402322 A AU2022402322 A AU 2022402322A AU 2022402322 A AU2022402322 A AU 2022402322A AU 2022402322 A1 AU2022402322 A1 AU 2022402322A1
Authority
AU
Australia
Prior art keywords
dose
tcr
range
fusion molecule
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022402322A
Other languages
English (en)
Inventor
Shaad ABDULLAH
Mohammed Dar
Shannon Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of AU2022402322A1 publication Critical patent/AU2022402322A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022402322A 2021-12-01 2022-11-30 Treatment Pending AU2022402322A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163285044P 2021-12-01 2021-12-01
US63/285,044 2021-12-01
US202263374222P 2022-08-31 2022-08-31
US63/374,222 2022-08-31
PCT/EP2022/083952 WO2023099622A1 (en) 2021-12-01 2022-11-30 Treatment

Publications (1)

Publication Number Publication Date
AU2022402322A1 true AU2022402322A1 (en) 2024-06-20

Family

ID=84688213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022402322A Pending AU2022402322A1 (en) 2021-12-01 2022-11-30 Treatment

Country Status (9)

Country Link
US (1) US20250333504A1 (https=)
EP (1) EP4441096A1 (https=)
JP (1) JP2024542682A (https=)
KR (1) KR20240114759A (https=)
AU (1) AU2022402322A1 (https=)
IL (1) IL312981A (https=)
MX (1) MX2024006799A (https=)
TW (1) TW202330589A (https=)
WO (1) WO2023099622A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519257A (zh) 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
TW202544042A (zh) 2024-03-13 2025-11-16 英商英美偌科有限公司 治療prame陽性癌症之方法
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
WO2017208018A1 (en) * 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
TW202330589A (zh) 2023-08-01
EP4441096A1 (en) 2024-10-09
JP2024542682A (ja) 2024-11-15
WO2023099622A1 (en) 2023-06-08
KR20240114759A (ko) 2024-07-24
US20250333504A1 (en) 2025-10-30
MX2024006799A (es) 2024-08-22
IL312981A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
US20250333504A1 (en) Treatment
TWI912619B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
US20240301027A1 (en) Treatment of mage-a4 positive cancer
CN116650628A (zh) 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
TWI899236B (zh) 通過投予pd-1抑制劑治療子宮頸癌的方法
CA3239837A1 (en) Treatment
EP4694926A1 (en) Combination for treatment and prevention of cancer
CN118510808A (zh) 治疗
JP2023540217A (ja) Ｐｄ－１阻害剤を投与することによりがんを処置する方法
WO2025027557A1 (en) Method of treating cutaneous melanoma
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
JP2026514110A (ja) がんの処置および予防のための組合せ
WO2025191519A1 (en) Method of treating prame-positive cancer
WO2025068803A1 (en) Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
Huang NKG2A: A Novel Immune Checkpoint Protein for Cancer Treatment
JP2025540235A (ja) がんの処置および予防のための組合せ
HK40098919A (zh) 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
HK40107230A (zh) 用於癌症的治疗和诊断方法以及组合物
AU2022239581A1 (en) Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
EP4297782A1 (en) Methods of treating lung cancer by administering a pd-1 inhibitor
HK40109234A (zh) 用於治疗癌症的方法和组合物
AU2022244191A1 (en) Therapeutic combination for treating cancer
AU2021219334A1 (en) Method of treatment of cancer or tumour
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌